Organon & Co. Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: PEO Joseph Morrissey; Other NEO average total compensation $4.15M.
- 2024-12-31: PEO Kevin Ali; PEO total compensation $17.12M; PEO compensation actually paid $16.38M; Other NEO average total compensation $4.42M.
- 2023-12-31: PEO Kevin Ali; PEO total compensation $14.83M; PEO compensation actually paid -$553.77K; Other NEO average total compensation $4.07M.
- 2022-12-31: PEO Kevin Ali; PEO total compensation $13.53M; PEO compensation actually paid $11.73M; Other NEO average total compensation $4.13M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Joseph Morrissey | $4.15M | $1.34M | $2368.00 | $15636.00 | $187.00M | AdjustedEBITDA $1.86B | 2026-04-24 | ||
| 2024-12-31 | Kevin Ali | $17.12M | $16.38M | $4.42M | $4.22M | $4805.00 | $12975.00 | $864.00M | $2.11B | 2026-04-24 |
| 2023-12-31 | Kevin Ali | $14.83M | -$553.77K | $4.07M | $761.71K | $4371.00 | $12639.00 | $1.02B | $2.00B | 2026-04-24 |
| 2022-12-31 | Kevin Ali | $13.53M | $11.73M | $4.13M | $3.73M | $7965.00 | $12052.00 | $917.00M | $2.23B | 2026-04-24 |
| 2021-12-31 | Kevin Ali | $18.55M | $14.26M | $5.31M | $4.04M | $8372.00 | $11488.00 | $1.35B | $1.44B | 2026-04-24 |
| 2024-12-31 | Kevin Ali | $17.12M | $16.38M | $4.42M | $4.22M | $48.05 | $129.75 | $864.00M | AdjustedEBITDA $2.11B | 2025-04-25 |
| 2023-12-31 | Kevin Ali | $14.83M | -$553.77K | $4.07M | $761.71K | $43.71 | $126.39 | $1.02B | $2.00B | 2025-04-25 |
| 2022-12-31 | Kevin Ali | $13.53M | $11.73M | $4.13M | $3.73M | $79.65 | $120.52 | $917.00M | $2.23B | 2025-04-25 |
| 2021-12-31 | Kevin Ali | $18.55M | $14.26M | $5.31M | $4.04M | $83.72 | $114.88 | $1.35B | $1.44B | 2025-04-25 |
| 2023-12-31 | Kevin Ali | $14.83M | -$553.77K | $4.07M | $761.71K | $43.71 | $126.39 | $1.02B | Adjusted EBITDA $2.00B | 2024-04-25 |
| 2022-12-31 | $13.53M | $11.73M | $4.13M | $3.73M | $79.65 | $120.52 | $917.00M | $2.23B | 2024-04-25 | |
| 2021-12-31 | $18.55M | $14.26M | $5.31M | $4.04M | $83.72 | $114.88 | $1.35B | $1.44B | 2024-04-25 | |
| 2022-12-31 | Kevin Ali | $14.95M | $11.55M | $4.49M | $3.67M | $79.65 | $120.52 | $917.00M | Adjusted EBITDA $2.23B | 2023-04-27 |
| 2021-12-31 | $16.85M | $14.18M | $4.83M | $4.01M | $83.72 | $114.88 | $1.35B | $1.44B | 2023-04-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |